The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
Abstract
Purpose: Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced non–small-cell lung cancer (NSCLC). For patients without progression, timing of second-line chemotherapy for optimum clinical benefit remains uncertain. This phase III, randomized trial assessed the efficacy and safety of docetaxel administered either immediately after GC or at disease progression. Patients and Methods: The chemotherapy-naïve patients enrolled had either stage IIIB NSCLC with pleural effusion or stage IV NSCLC. Gemcitabine (1,000 mg/m 2) was administered on days 1 and 8 followed by carboplatin (area under the curve = 5) on day 1. After four 21-day cycles, patients who did not have progression were randomly assigned either to an immediate docetaxel group (docetaxel 75 mg/m 2 on day 1 every 21 days, with maximum of six cycles) or to a delayed docetaxel group. The primary end point was overall survival (OS) measured from random assignment. Additional analyses included tumor response, toxicity, progression-free survival (PFS), and quality of life (QOL). Results: Enrollment totaled 566 patients; 398 patients completed GC; 309 patients were randomly assigned equally to the two docetaxel treatment groups. Toxicity profiles were generally comparable for the docetaxel groups. Median PFS for immediate docetaxel (5.7 months) was significantly greater (P = .0001) than for delayed docetaxel (2.7 months). Median OS for immediate docetaxel (12.3 months) was greater than for delayed docetaxel (9.7 months), but the difference was not statistically significant (P = .0853). QOL results were not statistically different (P = .76) between docetaxel groups. Conclusion: We observed a statistically significant improvement in PFS and a nonstatistically significant increase in OS when docetaxel was administered immediately after front-line GC, without increasing toxicity or decreasing QOL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citationCOMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,181
Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Bland, J. M., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.328.7447.1073 · Cited by 928
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Socinski, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 379
Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., Ciuleanu, T., Cucevic, B., Gyurkovits, K., Ulsperger, E., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.006 · Cited by 320
Smith, I. E., O’Brien, M. E. R., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., Norton, A., & Ashley, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1336 · Cited by 308
Hollen, P. J., Gralla, R. J., Kris, M. G., Cox, C., Belani, C. P., Grunberg, S. M., Crawford, J., & Neidhart, J. A. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2087::aid-cncr2820730813>3.0.co;2-x · Cited by 239
Belani, C. P., Barstis, J., Perry, M. C., La Rocca, R. V., Nattam, S. R., Rinaldi, D., Clark, R., & Mills, G. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.563 · Cited by 206
Park, J. O., Kim, S.-W., Ahn, J. S., Suh, C., Lee, J. S., Jang, J. S., Cho, E. K., Yang, S. H., Choi, J.-H., Heo, D. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8134 · Cited by 180
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
Westeel, V., Quoix, É., Moro‐Sibilot, D., Mercier, M., Breton, J.-L., Debieuvre, D., Richard, P., Haller, M. A., Milleron, B. J., Herman, D., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji096 · Cited by 141
Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
Ciuleanu, T., Brodowicz, T., Belani, C. P., Kim, J., Krzakowski, M. J., Laack, E., Wu, Y.-L. L. C., Peterson, P. M., Adachi, S., & Zielinski, C. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8011 · Cited by 98
Buccheri, G., Ferrigno, D., Curcio, A., Vola, F., & Rosso, A. (1989) · Cancer · Cited by 86
Grossi, F., Aita, M., Follador, A., Defferrari, C., Brianti, A., Sinaccio, G., & Belvedere, O. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-451 · Cited by 68
Edelman, M. J., Clark, J. I., Chansky, K., Albain, K. S., Bhoopalam, N., Weiss, G. R., Giguere, J. K., Kelly, K. L., Crowley, J. J., & Gandara, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0002 · Cited by 56
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg, M. B., & Edelman, M. J. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0020-6 · Cited by 41
Socinski, M. A., & Stinchcombe, T. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4015 · Cited by 38
Interim Analyses: An Update of an FDA Reviewer’s Experience and Perspective
Sankoh, A. J. (1999) · Drug Information Journal · doi:10.1177/009286159903300120 · Cited by 17
Obasaju, C. K., Ye, Z., Bloss, L. P., Monberg, M., & Curiel, R. E. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.n.037 · Cited by 11
Self-citationTreat, J., Belani, C. P., Schiller, J. H., Monberg, M., Cunneen, J. L., Chen, R., Ye, Z., & Obasaju, C. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7130 · Cited by 4
Self-citation
Cited by
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Metadata
- Authors
- Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova-Kazmierski, M., Treat, J., Obasaju, C. K., Marciniak, M., Gill, J., & Schiller, J. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-01
- Volume
- 27
- Issue
- 4
- Pages
- 591-598
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136023414
- Cited by
- 418
- References
- 28
- FWCI
- 43.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.